ApoB Targeting Cost-Effective for Primary Prevention of ASCVD
Overview
ApoB-guided lipid-lowering therapy intensification in primary prevention yielded the greatest gains in quality-adjusted life-years (QALYs) and was cost-effective compared to LDL-C and non–HDL-C strategies. The incremental cost-effectiveness ratio (ICER) for apoB was $30,300 per QALY gained, with significant reductions in ASCVD events over a lifetime horizon.
Background
Lipid-lowering therapy is a cornerstone of primary prevention for atherosclerotic cardiovascular disease (ASCVD). Traditional targets include low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C). Apolipoprotein B (apoB) has emerged as a potentially superior marker to guide treatment intensification. This study evaluated the cost-effectiveness and clinical outcomes of using apoB versus LDL-C and non–HDL-C targets in a large US primary prevention cohort.
Data Highlights
| Strategy | ASCVD Events | QALYs Gained | Incremental Cost ($ millions) | ICER ($/QALY) | Treatment Intensification (%) |
|---|---|---|---|---|---|
| LDL-C <100 mg/dL | 129,811 | Reference | Reference | Reference | 51 |
| Non–HDL-C <118 mg/dL | 129,194 | 965 additional | −2.1 (cost saving) | Dominant vs LDL-C | 57 |
| ApoB <78.7 mg/dL | 128,176 | 1,324 additional vs non–HDL-C | 40.2 | 30,300 vs non–HDL-C | 64 |
Key Findings
- ApoB-guided therapy prevented 1,018 more ASCVD events per 250,000 patients than non–HDL-C targeting.
- ApoB strategy yielded the highest QALYs gained among the three lipid targets.
- Incremental cost-effectiveness ratio for apoB vs non–HDL-C was $30,300 per QALY, well below common willingness-to-pay thresholds.
- Treatment intensification rates were highest with apoB (64%) compared to non–HDL-C (57%) and LDL-C (51%).
- Sex-specific ICERs showed apoB was cost-effective in both women ($35,900/QALY) and men ($26,600/QALY).
- Higher costs with apoB strategy were mainly due to longer life expectancy and extended preventive treatment, not testing costs.
Clinical Implications
Using apoB as a target for lipid-lowering therapy intensification in primary prevention may optimize ASCVD risk reduction and improve population health outcomes cost-effectively. Clinicians should consider apoB measurement to guide treatment decisions, particularly given its association with greater QALY gains and acceptable cost-effectiveness. Adoption of apoB targets could lead to more appropriate intensification of statin and adjunctive therapies.
Conclusion
ApoB-guided lipid-lowering therapy intensification in primary prevention offers superior clinical benefits and is cost-effective compared to LDL-C and non–HDL-C targets. These findings support incorporating apoB measurement into guideline-based risk management strategies.
References
- Luebbe et al., JAMA 2024 -- ApoB Goal Cost-Effective in Primary Prevention
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
